Back to Search
Start Over
MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer.
- Source :
- Clinical Epigenetics; 1/3/2024, Vol. 16 Issue 1, p1-14, 14p
- Publication Year :
- 2024
Details
- Language :
- English
- ISSN :
- 18687075
- Volume :
- 16
- Issue :
- 1
- Database :
- Supplemental Index
- Journal :
- Clinical Epigenetics
- Publication Type :
- Academic Journal
- Accession number :
- 174578314
- Full Text :
- https://doi.org/10.1186/s13148-023-01617-3